Market crash slumps biotech as investors yank $1.2B from funds
After soaring 11% on the highs of JPM hype and mega-sized mergers and acquisitions, the Nasdaq Biotech Index is tumbling in February.
That rapid downshift …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
